$TYRA
Tyra Biosciences, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024056971 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.535M $5.119M
YoY Change 30.39%
% of Gross Profit
Research & Development $18.00M $17.20M
YoY Change 47.98% 65.29%
% of Gross Profit
Depreciation & Amortization $100.0K $122.0K
YoY Change 0.0% 46.99%
% of Gross Profit
Operating Expenses $23.53M $22.32M
YoY Change 46.95% 55.73%
Operating Profit -$23.53M -$22.32M
YoY Change 46.95% 55.73%
Interest Expense $4.830M $4.130M
YoY Change 74.81% 68.23%
% of Operating Profit
Other Income/Expense, Net $4.830M $4.130M
YoY Change 76.15% 68.3%
Pretax Income -$18.70M -$18.19M
YoY Change 40.91% 53.13%
Income Tax
% Of Pretax Income
Net Earnings -$18.70M -$18.19M
YoY Change 40.91% 53.13%
Net Earnings / Revenue
Basic Earnings Per Share -$0.32 -$0.35
Diluted Earnings Per Share -$0.32 -$0.35
COMMON SHARES
Basic Shares Outstanding 52.54M 52.52M
Diluted Shares Outstanding 58.67M 52.23M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $373.8M $382.5M
YoY Change 60.83% 58.24%
Cash & Equivalents $99.49M $254.4M
Short-Term Investments $274.3M $128.1M
Other Short-Term Assets $4.778M $8.316M
YoY Change -42.66% 66.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $378.6M $390.8M
YoY Change 57.25% 58.4%
LONG-TERM ASSETS
Property, Plant & Equipment $1.898M $1.593M
YoY Change 80.08% 52.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.693M $4.958M
YoY Change 441.92% 27.98%
Total Long-Term Assets $13.89M $13.96M
YoY Change 49.87% 67.3%
TOTAL ASSETS
Total Short-Term Assets $378.6M $390.8M
Total Long-Term Assets $13.89M $13.96M
Total Assets $392.5M $404.7M
YoY Change 56.98% 58.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.577M $2.879M
YoY Change 9.51% 124.92%
Accrued Expenses $8.805M $5.837M
YoY Change 122.07% 143.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.38M $8.716M
YoY Change 92.08% 136.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.00K $29.00K
YoY Change -81.48% -79.14%
Total Long-Term Liabilities $20.00K $29.00K
YoY Change -81.48% -79.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.38M $8.716M
Total Long-Term Liabilities $20.00K $29.00K
Total Liabilities $16.42M $14.86M
YoY Change 43.51% 137.22%
SHAREHOLDERS EQUITY
Retained Earnings -$201.7M -$183.0M
YoY Change 66.92% 70.13%
Common Stock $578.0M $572.9M
YoY Change 60.8% 60.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $376.0M $389.9M
YoY Change
Total Liabilities & Shareholders Equity $392.5M $404.7M
YoY Change 56.98% 58.69%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$18.70M -$18.19M
YoY Change 40.91% 53.13%
Depreciation, Depletion And Amortization $100.0K $122.0K
YoY Change 0.0% 46.99%
Cash From Operating Activities -$10.26M -$22.03M
YoY Change 6.69% 123.7%
INVESTING ACTIVITIES
Capital Expenditures $470.0K $136.0K
YoY Change 993.02% 231.71%
Acquisitions
YoY Change
Other Investing Activities -$144.5M $18.21M
YoY Change
Cash From Investing Activities -$145.0M $18.07M
YoY Change 337088.37% -44180.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 373.0K 200.3M
YoY Change 0.81% 53175.27%
NET CHANGE
Cash From Operating Activities -10.26M -22.03M
Cash From Investing Activities -145.0M 18.07M
Cash From Financing Activities 373.0K 200.3M
Net Change In Cash -154.9M 196.4M
YoY Change 1567.48% -2164.34%
FREE CASH FLOW
Cash From Operating Activities -$10.26M -$22.03M
Capital Expenditures $470.0K $136.0K
Free Cash Flow -$10.73M -$22.16M
YoY Change 11.08% 124.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Assets Current
AssetsCurrent
211671000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001863127
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40800
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
TYRA BIOSCIENCES, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1476348
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2656 State Street
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
CY2024Q1 dei City Area Code
CityAreaCode
619
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
728-4760
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
TYRA
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52539804
CY2024Q1 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
254366000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58006000
CY2024Q1 us-gaap Marketable Securities
MarketableSecurities
128096000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
145463000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8316000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8202000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
390778000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1593000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1628000
CY2024Q1 tyra Right Of Use Asset
RightOfUseAsset
6412000
CY2023Q4 tyra Right Of Use Asset
RightOfUseAsset
6526000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4958000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5032000
CY2024Q1 us-gaap Assets
Assets
404741000
CY2023Q4 us-gaap Assets
Assets
225857000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2879000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4662000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
370000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
280000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5467000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10391000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8716000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15333000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6117000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6216000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
29000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46000
CY2024Q1 us-gaap Liabilities
Liabilities
14862000
CY2023Q4 us-gaap Liabilities
Liabilities
21595000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52521050
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43099055
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52474533
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43024634
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
572902000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
368707000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
381000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183022000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-164830000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
389879000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
204262000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
404741000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
225857000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17203000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10408000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5119000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3926000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
22322000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
14334000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22322000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14334000
CY2024Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
4130000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
2454000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4130000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2454000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-18192000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-387000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18579000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11880000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52228934
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52228934
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42394623
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42394623
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
257829000
CY2023Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
376000
CY2023Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
32000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2433000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
248790000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
204262000
CY2024Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
484000
CY2024Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
17000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4115000
CY2024Q1 tyra Availableforsaledebtsecuritiesnetunrealizedloss
Availableforsaledebtsecuritiesnetunrealizedloss
-387000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-18192000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
389879000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-18192000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
122000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4115000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2433000
CY2024Q1 tyra Accretion On Marketable Securities Net
AccretionOnMarketableSecuritiesNet
-1229000
CY2023Q1 tyra Accretion On Marketable Securities Net
AccretionOnMarketableSecuritiesNet
0
CY2024Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
43000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1530000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6906000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2022000
CY2024Q1 tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
105000
CY2023Q1 tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
9000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22028000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9847000
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
11791000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
-0
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30000000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
136000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18073000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41000
CY2024Q1 tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
484000
CY2023Q1 tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
376000
CY2024Q1 tyra Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Private Placement
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement
200000000
CY2023Q1 tyra Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Private Placement
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement
0
CY2024Q1 tyra Payments Of Issuance Costs For Common Stock And Pre Funded Warrants From Private Placement
PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement
169000
CY2023Q1 tyra Payments Of Issuance Costs For Common Stock And Pre Funded Warrants From Private Placement
PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
200315000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
376000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
196360000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9512000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59006000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252213000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
255366000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
242701000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
254366000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
241701000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
255366000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
242701000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2024Q1 tyra Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
17000
CY2023Q1 tyra Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
32000
CY2024Q1 tyra Issuance Costs Related To Private Placement Included In Accounts Payable And Accrued And Other Current Liabilities
IssuanceCostsRelatedToPrivatePlacementIncludedInAccountsPayableAndAccruedAndOtherCurrentLiabilities
251000
CY2023Q1 tyra Issuance Costs Related To Private Placement Included In Accounts Payable And Accrued And Other Current Liabilities
IssuanceCostsRelatedToPrivatePlacementIncludedInAccountsPayableAndAccruedAndOtherCurrentLiabilities
0
CY2024Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-02
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
3000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
145463000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
1000000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
1000000
CY2024Q1 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2023 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
128102000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
70000
CY2024Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
76000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
128096000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
145082000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
384000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
169500
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.93
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
92280
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.81
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
6163
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.64
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8347499
CY2024Q1 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
29009000
CY2024Q1 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
76000
CY2024Q1 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2024Q1 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2024Q1 us-gaap Fair Value Option Credit Risk Gains Losses On Assets
FairValueOptionCreditRiskGainsLossesOnAssets
29009000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
76000
CY2023Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
9939000
CY2023Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2023Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2023Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2023 us-gaap Fair Value Option Credit Risk Gains Losses On Assets
FairValueOptionCreditRiskGainsLossesOnAssets
9939000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
6
CY2024Q1 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
29000000
CY2024Q1 tyra Accrued Interest Available For Sale Securities
AccruedInterestAvailableForSaleSecurities
1500000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2519000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2435000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
926000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
807000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1593000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1628000
CY2024Q1 us-gaap Depreciation
Depreciation
100000
CY2023Q1 us-gaap Depreciation
Depreciation
100000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.36
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
56838000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3657819
CY2024Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1041000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5117000
CY2024Q1 tyra Accrued Research And Development
AccruedResearchAndDevelopment
3893000
CY2023Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
4848000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
221000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
132000
CY2024Q1 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
312000
CY2023Q4 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
294000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5467000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10391000
CY2024Q1 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
8347499
CY2023Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
8276442
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21620354
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13083154
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8276442
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.07
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
40420000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.6
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
32237000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8347499
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.36
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
56838000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.886
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4115000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2433000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
39100000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
380000
CY2024Q1 tyra Stockholders Equity Increase Decrease In Common Stock Percent
StockholdersEquityIncreaseDecreaseInCommonStockPercent
0.01
CY2024Q1 tyra Purchase Of Common Stock Through Payroll Deduction
PurchaseOfCommonStockThroughPayrollDeduction
0.15
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.85
CY2024Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
100000
CY2023Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
100000
CY2024Q1 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
46517
CY2023Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
74421
CY2024Q1 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
29000
CY2023Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
46000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-18192000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2024Q1 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
52275451
CY2023Q1 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
42690767
CY2024Q1 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
0
CY2023Q1 tyra Weighted Average Unvested Restricted Common Stock Subject To Repurchase
WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase
-3274
CY2024Q1 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-46517
CY2023Q1 tyra Weighted Average Unvested Common Stock Issued Upon Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
-292870
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52228934
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52228934
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42394623
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42394623
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8396929
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6357982
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
239000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
83000
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
24000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
22000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
32000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
14000
CY2024Q1 us-gaap Lease Cost
LeaseCost
295000
CY2023Q1 us-gaap Lease Cost
LeaseCost
119000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
638000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
873000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
899000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
926000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
954000
CY2024Q1 tyra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
5027000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9317000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2830000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
6487000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
370000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6117000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y10M24D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0807
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0807
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-056971-index-headers.html Edgar Link pending
0000950170-24-056971-index.html Edgar Link pending
0000950170-24-056971.txt Edgar Link pending
0000950170-24-056971-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tyra-20240331.htm Edgar Link pending
tyra-20240331.xsd Edgar Link pending
tyra-ex10_3.htm Edgar Link pending
tyra-ex31_1.htm Edgar Link pending
tyra-ex31_2.htm Edgar Link pending
tyra-ex32_1.htm Edgar Link pending
tyra-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tyra-20240331_htm.xml Edgar Link completed